(Q34102132)

31 July 2017

title

Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer (English)

1 reference

31 July 2017

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer (English)

1 reference

https://api.crossref.org/works/10.3904/KJIM.2010.25.3.294

non-small-cell lung carcinoma

10 July 2024

main subject

1 reference

Junshik Hong

1

1 reference

31 July 2017

Sun Young Kyung

2

1 reference

31 July 2017

Sang Pyo Lee

3

1 reference

31 July 2017

Jeong Woong Park

4

1 reference

31 July 2017

Sung Hwan Jung

5

1 reference

31 July 2017

Jae-Ik Lee

6

1 reference

31 July 2017

Se Hoon Park

7

1 reference

31 July 2017

Sun Jin Sym

8

1 reference

31 July 2017

Jinny Park

9

1 reference

31 July 2017

Eun Kyung Cho

10

1 reference

31 July 2017

Dong Bok Shin

11

1 reference

31 July 2017

Jae Hoon Lee

12

1 reference

31 July 2017

language of work or name

1 reference

31 August 2010

1 reference

full work available at URL

31 July 2017

https://www.kjim.org/upload/kjim-25-294.pdf

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830227

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20830227/pdf/?tool=EBI

10 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830227

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20830227/?tool=EBI

10 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830227

https://europepmc.org/articles/PMC2932943

10 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830227

https://europepmc.org/articles/PMC2932943?pdf=render

10 July 2024

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830227

http://synapse.koreamed.org/pdf/10.3904/kjim.2010.25.3.294

10 July 2024

1 reference

https://api.crossref.org/works/10.3904/KJIM.2010.25.3.294

http://synapse.koreamed.org/DOIx.php?id=10.3904/kjim.2010.25.3.294

10 July 2024

1 reference

https://api.crossref.org/works/10.3904/KJIM.2010.25.3.294

http://www.kjim.org/upload/kjim-25-294.pdf

10 July 2024

1 reference

https://api.crossref.org/works/10.3904/KJIM.2010.25.3.294

The Korean journal of internal medicine

10 July 2024

published in

1 reference

31 July 2017

volume

25

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

294-300

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

31 July 2017

copyright license

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Considerations for second-line therapy of non-small cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Erlotinib in previously treated non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

5 July 2018

Cancer statistics, 2005

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Erlotinib for the treatment of non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Cancer control activities in the Republic of Korea

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2932943

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20830227

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20830227

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

1 reference

release_u6w3faf7t5ftzhs4hbsj3uz6ai

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u6w3faf7t5ftzhs4hbsj3uz6ai

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

2932943

1 reference

31 July 2017

1 reference